CJC-no Dac (5MG)/IPAMORELIN (5MG) BLEND

CJC-1295 No DAC combined with Ipamorelin is a synergistic GH pulse stack that stimulates natural growth hormone release through two independent synergistic pathways. Rather than relying on a single receptor system, this combination activates both the GHRH and ghrelin pathways simultaneously, producing a GH pulse that is significantly larger than either peptide can achieve alone.

What are these research compounds?

CJC-1295 (no DAC):

• GHRH receptor agonist: binds to GHRH receptors on pituitary somatotroph cells, stimulating them to produce and release growth hormone
• Pulse amplitude: increases the amplitude (size) of each GH pulse without disrupting the natural pulsatile pattern
• Short half-life (~30 min): the no-DAC form produces discrete GH pulses that mimic natural physiology, unlike the DAC version which creates sustained elevation
• IGF-1 elevation: sustained use increases circulating IGF-1 levels, supporting tissue repair, muscle protein synthesis, and fat metabolism

Ipamorelin:

• Ghrelin receptor agonist (GHRP): mimics the hunger hormone ghrelin to trigger GH release from a completely different receptor than CJC-1295
• Selective GH release: unlike other GHRPs (GHRP-2, GHRP-6, Hexarelin), Ipamorelin does not significantly elevate cortisol or prolactin, making it the cleanest GHRP available
• Dose-dependent response: produces a predictable, dose-dependent GH release with minimal desensitization over time
• Mild hunger signaling: may slightly increase appetite through ghrelin mimicry, but far less than GHRP-6 or GHRP-2

How the Stack Works
CJC-1295 No DAC (also called Mod GRF 1-29) is a growth hormone-releasing hormone (GHRH) analog that signals the pituitary to produce and release GH, while Ipamorelin is a selective growth hormone secretagogue (GHS) that activates the ghrelin receptor (GHS-R1a) to trigger GH release from stored reserves. Together, they produce a GH pulse significantly larger than either peptide alone, without raising cortisol or prolactin, and without causing extreme hunger associated with other GHRPs. CJC-1295 tells the pituitary “make more GH and release bigger pulses” via the GHRH pathway. Ipamorelin simultaneously tells the pituitary “release GH now” via the ghrelin pathway. When both signals arrive together, the pituitary responds with a GH pulse that is substantially larger than either signal could produce alone. Research on GHRH + GHRP combinations has demonstrated this synergistic effect, with combined administration producing GH output that exceeds the simple sum of each peptide’s individual effect.

Benefits and Considerations
Produces 2–3x more GH than either peptide alone, supporting sleep quality, recovery, body composition, and anti-aging goals.
Short-acting No DAC version preserves natural GH pulse patterns, avoiding prolonged supra-physiological GH elevation.
The stack is selective and clean, minimizing side effects like cortisol spikes, prolactin elevation, or excessive appetite.
No randomized clinical trials have evaluated this exact combination, so protocols are based on research peptide studies and community experience.
This stack is widely used in research and experimental settings to optimize natural GH production safely and effectively, provided dosing and storage guidelines are carefully followed.